Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$7.31
-1.1%
$6.32
$3.76
$46.80
$45.19M2.77210,890 shs51,768 shs
AlloVir, Inc. stock logo
ALVR
AlloVir
$2.58
-3.4%
$3.62
$7.96
$24.15
$13.01M0.6315,279 shs2,793 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$7.76
+1.6%
$8.12
$6.85
$21.01
$450.87M-0.08517,678 shs319,885 shs
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
$20.01
$20.00
$4.95
$20.68
$957.54M-0.94847,595 shs1 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$0.93
+0.2%
$0.89
$0.52
$1.98
$269.87M4.184.58 million shs3.47 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-1.08%-4.19%+39.24%+12.81%-26.90%
AlloVir, Inc. stock logo
ALVR
AlloVir
-3.37%+3.61%-11.03%-68.03%-84.74%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+1.57%-2.02%-11.31%+3.60%-52.42%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
0.00%0.00%0.00%0.00%0.00%
Ocugen, Inc. stock logo
OCGN
Ocugen
+0.25%-10.92%+10.65%+45.04%-42.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
4.2207 of 5 stars
3.53.00.04.82.71.70.0
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
2.223 of 5 stars
3.51.00.00.02.71.70.6
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
1.3297 of 5 stars
3.51.00.00.02.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
3.00
Buy$70.00857.59% Upside
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$30.00286.60% Upside
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
0.00
N/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
3.00
Buy$6.00547.67% Upside

Current Analyst Ratings Breakdown

Latest OCGN, FMTX, CGEM, ALVR, and ALGS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/11/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
5/12/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $24.00
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/16/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$3.94M11.34N/AN/A($7.50) per share-0.97
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$10.14 per shareN/A
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
$100.56M9.52N/AN/A$10.51 per share1.90
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.05M66.80N/AN/A$0.10 per share9.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$131.21M-$17.51N/AN/AN/A-1,628.75%14.67%7.19%8/5/2025 (Estimated)
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/A-71.03%-61.27%8/7/2025 (Estimated)
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/A
Ocugen, Inc. stock logo
OCGN
Ocugen
-$54.05M-$0.19N/AN/AN/A-1,271.12%-223.00%-92.20%8/6/2025 (Estimated)

Latest OCGN, FMTX, CGEM, ALVR, and ALGS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.05+$0.01-$0.05N/A$1.48 million
5/8/2025Q1 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.78-$0.74+$0.04-$0.74N/AN/A
5/6/2025Q1 2025
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/AN/AN/AN/AN/A
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/A
7.56
7.56
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
11.62
11.62
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
N/A
12.74
12.74
Ocugen, Inc. stock logo
OCGN
Ocugen
1.74
2.60
2.60

Institutional Ownership

CompanyInstitutional Ownership
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
60.43%
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
87.39%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%

Insider Ownership

CompanyInsider Ownership
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
4.80%
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
7.16%
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
5.79%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
906.11 million5.82 millionNo Data
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.01 million54.79 millionOptionable
Forma Therapeutics Holdings, Inc. stock logo
FMTX
Forma Therapeutics
16647.85 million45.08 millionNot Optionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80292.03 million279.12 millionOptionable

Recent News About These Companies

HC Wainwright Reiterates Buy Rating for Ocugen (NASDAQ:OCGN)
Ocugen: Three Potential Gene-Therapy Filings By 2028
Ocugen To Present at BIO International Convention 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aligos Therapeutics stock logo

Aligos Therapeutics NASDAQ:ALGS

$7.31 -0.08 (-1.08%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$7.56 +0.25 (+3.35%)
As of 07/2/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

AlloVir stock logo

AlloVir NASDAQ:ALVR

$2.58 -0.09 (-3.37%)
As of 07/1/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$7.76 +0.12 (+1.57%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$7.76 0.00 (-0.06%)
As of 07/2/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Forma Therapeutics stock logo

Forma Therapeutics NASDAQ:FMTX

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$0.93 +0.00 (+0.25%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$0.92 -0.01 (-0.69%)
As of 06:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.